Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Income: 2021-2025

Historic Net Income for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.4 million.

  • Krystal Biotech's Net Income rose 192.12% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 279.88%. This contributed to the annual value of $89.2 million for FY2024, which is 715.58% up from last year.
  • Latest data reveals that Krystal Biotech reported Net Income of $79.4 million as of Q3 2025, which was up 107.05% from $38.3 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Net Income registered a high of $80.7 million during Q3 2023, and its lowest value of -$50.0 million during Q1 2022.
  • Moreover, its 3-year median value for Net Income was $27.2 million (2024), whereas its average is $21.9 million.
  • In the last 5 years, Krystal Biotech's Net Income crashed by 215.99% in 2022 and then surged by 3,730.15% in 2025.
  • Krystal Biotech's Net Income (Quarterly) stood at -$21.8 million in 2021, then tumbled by 46.99% to -$32.1 million in 2022, then surged by 127.12% to $8.7 million in 2023, then skyrocketed by 423.62% to $45.5 million in 2024, then surged by 192.12% to $79.4 million in 2025.
  • Its Net Income was $79.4 million in Q3 2025, compared to $38.3 million in Q2 2025 and $35.7 million in Q1 2025.